
Veeva Systems (VEEV) Stock Forecast & Price Target
Veeva Systems (VEEV) Analyst Ratings
Bulls say
Veeva Systems is poised for strong growth in the life sciences industry due to its best-of-breed offerings and efficient solutions that displace outdated systems. With a diverse client base and increased demand in the bio-pharma industry, VEEV is well-positioned to maintain competitive advantage and drive revenue growth. Risks may come from larger competitors, but potential aggressive share repurchases and demand for its solutions make VEEV a strong buy.
Bears say
Veeva Systems is facing stiff competition from other companies specializing in healthcare, such as IQVIA (IQV), Definitive Healthcare (DH), and Cognizant (CTSH), which poses a risk to its revenue growth and market share. Additionally, the current macroeconomic environment, including drug pricing reform and a challenged bio-pharma funding environment, may negatively impact demand for Veeva's services. Although the company has a diverse client base and is well-positioned to benefit from the recovery of the bio-pharma industry, it may face challenges in retaining clients and maintaining its pricing strategy. Therefore, the financial analyst has a negative outlook on Veeva System's stock due to potential threats to its revenue growth and profitability.
This aggregate rating is based on analysts' research of Veeva Systems and is not a guaranteed prediction by Public.com or investment advice.
Veeva Systems (VEEV) Analyst Forecast & Price Prediction
Start investing in Veeva Systems (VEEV)
Order type
Buy in
Order amount
Est. shares
0 shares